Clinical trials: Antivirals/HIV
HIV Infections
Effects of BufferGel and PRO 2000/5 Gel in Men
The purpose of this study is to find out if there are any bad effects when BufferGel or PRO 2000/5 Gel are applied to the penis of HIV-infected men.
- Trial name
- NCT00016536
- Testing
- Naphthalene 2-sulfonate polymer, Carbopol polymer
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children
Cohort I: The purpose of this study is to see how safe it is to combine 2 anti-HIV medications, efavirenz (EFZ) and nelfinavir (NFV) to treat HIV-positive children and to find an appropriate dose of EFZ to use in combination with…
- Trial name
- NCT00000893
- Testing
- Nelfinavir mesylate, Efavirenz
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 103 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression
In HIV-infected patients, enhanced PD-1 expression of T cells correlates with T cell depletion, as evidenced by reduced virus-specific proliferative capacity and decreased cytokine expression.Targeting PD-L1 drugs to block…
- Trial name
- NCT05129189
- Testing
- ASC22 group
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Public Health Clinical Center
Acquired Immune Deficiency Syndrome, HIV Infections
Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients
This study will recruit 520 treatment-naive and 150 treatment-experienced patients to take the first line or second line of antiviral therapy.
- Trial name
- NCT00872417
- Testing
- first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT), second line ARV therapy (3TC+TDF+LPV/RTV)
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Peking Union Medical College
HIV Infections, Hepatitis B
Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
This study will investigate the safety and effectiveness of using adefovir dipivoxil (ADV), pegylated interferon (PEG-INF), and ribavirin (RBV) in patients triple-infected with hepatitis B virus (HBV), hepatitis C virus (HCV)…
- Conditions
- HIV Infections, Hepatitis B, Hepatitis C
- Trial name
- NCT00051077
- Testing
- Adefovir dipivoxil, Peginterferon-alfa-2A, Ribavirin
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection
This study will try to define how and where HIV infection persists in the body by determining: 1) if there are cells where HIV can live for long periods of time without being seen and destroyed by the immune system; 2) if there…
- Trial name
- NCT00001644
- Testing
- Indinavir, Zidovudine, Lamivudine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults
UB-421 subcutaneous formulation (UB-421 SC) is developed to provide HIV infected patients a more convenient drug delivery method.
- Trial name
- NCT04620291
- Testing
- UB-421 SC
- Volunteers
- 18 people
- Sponsor
- United BioPharma
HIV Infections
The Safety and Effectiveness of Different Doses of Vitamin C in HIV-Infected Patients
This is a study to evaluate the tolerance and antiviral effect of oral vitamin C in HIV-infected.
- Trial name
- NCT00001070
- Testing
- Oral Vitamin C
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV -1 Infection
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV).
- Trial name
- NCT07392372
- Testing
- BNT351
- Where
- 6 sites in United States, Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
To explore the possibility to overcome CYP3A-mediated resistance to anticancer drugs in pancreatic cancer, we will investigate the pharmacokinetics, safety, tolerability, and efficacy of nanoparticle albumin-bound paclitaxel…
- Conditions
- CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- IntenSify (NCT05494866)
- Testing
- Cobicistat Oral Tablet, Gemcitabin, Nab paclitaxel
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- German Cancer Research Center
HIV Infection, Endothelial Dysfunction
RAltegravir Switch STudy: Effects on Endothelial Recovery
Treatment with HIV-infection with protease inhibitors is associated with high blood lipids and higher chance for cardiovascular complications.
- Trial name
- RASSTER (NCT01453933)
- Testing
- raltegravir
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- UMC Utrecht
Cytomegalovirus Retinitis, HIV Infections
Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome
To explore the safety and usefulness of foscarnet, an antiviral agent, in the treatment of cytomegalovirus (CMV) retinitis. Untreated CMV retinitis is a rapidly progressive, blinding disease in AIDS patients.
- Trial name
- NCT00000726
- Testing
- Foscarnet sodium
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
3TC (Lamivudine; GR109714X) Open-Label Program
To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies.
- Trial name
- NCT00002108
- Testing
- Lamivudine, Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV Infections
Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily
To evaluate the proportion of patients with virological failure after 48 weeks of treatment with the combination of efavirenz 600 mg + lamivudine (3TC) 300 mg + abacavir 600 mg once daily as an antiretroviral simplification…
- Trial name
- NCT00314626
- Testing
- efavirenz, Abacavir+lamivudine
- Where
- 16 sites in Spain
- Volunteers
- 99 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV Infections
A Study of PMPA in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give PMPA to HIV-infected patients. This study also examines how the body handles PMPA.
- Trial name
- NCT00002180
- Testing
- Tenofovir
- Where
- 2 sites in United States
- Sponsor
- Gilead Sciences
HIV Infections
A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine
The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz (EFV) when both are used with zidovudine (ZDV) and lamivudine (3TC).
- Trial name
- NCT00013897
- Testing
- Atazanavir, Lamivudine/Zidovudine, Efavirenz
- Where
- 99 sites in United States, Austria and 22 more
- Sponsor
- Bristol-Myers Squibb
Leukemia, Lymphoma
Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer
RATIONALE: Antiviral agents are drugs that act against viruses and may be an effective treatment for HIV. Peripheral stem cell transplantation or umbilical cord blood transplantation may be able to replace immune cells that were…
- Trial name
- NCT00003435
- Testing
- anti-thymocyte globulin, melphalan, antiviral therapy
- Where
- United States
- Sponsor
- Duke University
HIV Infections
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3
To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.
- Trial name
- NCT00000625
- Testing
- Zidovudine, Zalcitabine, Didanosine
- Where
- 58 sites in United States, Puerto Rico and 1 more
- Volunteers
- 2,100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers
Infection by both HIV and hepatitis C virus (HCV)is frequent due to similar transmission modes. Near 20% of people living with HIV are also infected by HCV.
- Trial name
- NCT01627717
- Testing
- Maraviroc (5 days), Maraviroc and boceprevir (14 days)
- Where
- Canada
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Antivirals/HIV
Drug Interaction Study
The purpose of this study is to evaluate the exposure of rifabutin (RIB) when administered with atazanavir and ritonavir (ATV/RTV)
- Trial name
- NCT00646776
- Testing
- Rifabutin, Rifabutin + Atazanavir + Ritonavir
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb